Reference drug programs: effectiveness and policy implications. - Wikidata - awgldk - TriplyDB

Reference drug programs: effectiveness and policy implications.

Reference drug programs: effectiveness and policy implications.

http://www.wikidata.org/entity/Q33908085

about

Comprehensive taxonomy and worldwide trends in pharmaceutical policies in relation to country income status.Comparison of tiered formularies and reference pricing policies: a systematic review.Developments in post-marketing comparative effectiveness research Effectiveness, safety and cost of drug substitution in hypertension Addressing cost-related barriers to prescription drug use in Canada.The impact of reference-pricing systems in Europe: a literature review and case studies.Patients' knowledge and attitude towards therapeutic reference pricing system in Slovenia.Ethical issues raised in addressing the needs of people with serious mental disorders in complex emergencies.Does knowledge of medication prices predict physicians' support for cost effective prescribing policies.Initiatives to enhance renin-angiotensin prescribing efficiency in Austria: impact and implications for other countries.Pharmaceutical Price Schemes in Europe: Time for a 'Continental' One?

P2860

Q33730376-0ADBD143-7FFB-46B1-8BAE-6ABC8B4E9DE4 Q33908282-979E0748-D591-43AC-A77D-6FF382579A3A Q34001867-12997EE3-9DCE-44E8-8AEB-8AA2DF3AF7A3 Q34174844-87C7B71C-0F9C-42CF-AD35-B6CEB40F1919 Q37614006-726EA1F3-E4D5-4049-9CA1-B5B7FB24FBE9 Q37958057-4EFC63D5-77FF-44DB-AC11-DB6ABAC0A1C1 Q40630092-A95D7817-DF33-409D-A991-74D9111F6B44 Q41978061-A7B344F7-2D2D-4923-8BEA-D743FDF2D8D0 Q42612841-7DBC86B2-84CA-4CA7-BE61-B83BA01391EC Q43102979-D345574D-1E89-4861-A60F-5D6D10CD3E3C Q53195648-CB8B972F-AA28-41F7-9C5E-EB0AAC78D2A7

P2860

Reference drug programs: effectiveness and policy implications.

http://www.wikidata.org/entity/Q33908085

description

2006 nî lūn-bûn

@nan

2006 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Reference drug programs: effectiveness and policy implications.

@ast

Reference drug programs: effectiveness and policy implications.

@en

type

label

Reference drug programs: effectiveness and policy implications.

@ast

Reference drug programs: effectiveness and policy implications.

@en

prefLabel

Reference drug programs: effectiveness and policy implications.

@ast

Reference drug programs: effectiveness and policy implications.

@en

P1433

Q33908085-27884767-101E-4634-B3D4-8B567C737545

P1476

Q33908085-1500C9CB-5132-4CCA-87C0-8D0D61E266A0

P2093

Q33908085-7409C5CC-05AA-4EF2-A076-191D045C89AD

P2860

Q33908085-034C5AD2-F446-4AD1-81F1-F2F55429364E

Q33908085-0823F670-577A-43CA-8FDC-BBF9DAB4DC43

Q33908085-181A463B-5AAC-45F8-9701-0DA56DF03513

Q33908085-262F79D2-DDC5-402D-8BA5-C0D777F4BC08

Q33908085-27946E3D-2301-45F7-AD07-F3879C68E1CC

Q33908085-28950FDD-A083-46A7-8AF2-27C4F54389D8

Q33908085-2FFEBDBB-6600-468F-9417-A8CEEF9B7C79

Q33908085-41C9D9E8-17E6-41D1-8412-DC68BA9F8147

Q33908085-4625E08B-F6D9-484D-8B26-7E7189ED559B

Q33908085-480EB2A1-46D6-4D70-85E4-F421BC5D98F1

P304

Q33908085-2D906479-17AC-49B3-AAAF-0E6FFE97FF89

P31

Q33908085-DA14E962-08D8-4111-9A80-D9D1ECCB8E40

P356

Q33908085-2A93586B-5E6B-4E0E-8FB2-831D8E988FD3

P433

Q33908085-4D9154E3-996C-42F8-8DC2-2243927FECD9

P478

Q33908085-A787A8A5-C246-43FE-8E23-89D8CCB475DD

P577

Q33908085-DE04F85C-56DD-4F6E-B216-DF05F7BED813

P5875

Q33908085-AE19C487-4FF6-4469-9486-A4DE1133CD46

P698

Q33908085-1A604515-25E1-4FC9-BEB8-CACBBDE9F7EE

P932

Q33908085-3346A004-3465-4392-9C4A-1C942742D5FC

P356

J.HEALTHPOL.2006.05.001

P1433

P1476

Reference drug programs: effectiveness and policy implications.

@en

P2093

Sebastian Schneeweiss

http://www.w3.org/2001/XMLSchema#string

P2860

Why we need observational studies to evaluate the effectiveness of health care

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

Impact of reference-based pricing of nitrates on the use and costs of anti-anginal drugs

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

Consequences of implementing a drug budget for office-based physicians in Germany.

The German experience in reference pricing.

What is Germany's experience on reference based drug pricing and the etiology of adverse health outcomes or substitution?

The Medicare prescription drug benefit: how will the game be played?

Impact of reference-based pricing for histamine-2 receptor antagonists and restricted access for proton pump inhibitors in British Columbia

Statistics and drug utilization: are prescribing rates really that high?

P304

17-28

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.HEALTHPOL.2006.05.001

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

81

http://www.w3.org/2001/XMLSchema#string

P577

2006-06-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7006970

http://www.w3.org/2001/XMLSchema#string

P698

16777256

http://www.w3.org/2001/XMLSchema#string

P932

2884180

http://www.w3.org/2001/XMLSchema#string